A5045735997- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- Eosinophilic Disorders and Syndromes
- Chronic Myeloid Leukemia Treatments
- Pharmacogenetics and Drug Metabolism
- Hematological disorders and diagnostics
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Transplantation: Methods and Outcomes
- COVID-19 Clinical Research Studies
- Eosinophilic Esophagitis
- Pharmaceutical Economics and Policy
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Multiple Myeloma Research and Treatments
- Statistical Methods in Clinical Trials
- T-cell and Retrovirus Studies
- Muscle and Compartmental Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cancer-related Molecular Pathways
- Phagocytosis and Immune Regulation
Instituto de Investigación Marqués de Valdecilla
2021-2025
Marqués de Valdecilla University Hospital
2021-2024
Instituto de Investigación Biomédica de Salamanca
2024
Centro de Investigación Biomédica en Red de Cáncer
2024
Hospital Sierrallana
2009-2012
Newcastle upon Tyne Hospitals NHS Foundation Trust
2008
Universidad Autónoma de Madrid
1995-2001
Spanish Society of Hematology and Hemotherapy
1999
Hospital Universitario Puerta de Hierro Majadahonda
1997-1998
The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring avert adverse effects maintain efficacy. Polymorphisms VKORC1 CYP2C9 jointly account for about 40% of the interindividual requirements. To date, several pharmacogenetic-guided dosing algorithms derivatives, predominately warfarin, have been developed. However, potential benefit these terms...
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the slow and progressive accumulation of monoclonal apparently mature, CD5+ B lymphocytes. The majority circulating cells appear to be nondividing, it has been suggested that a prolonged life span mainly responsible for leukemic cells. However, spontaneous programmed cell death apoptosis occurs when are cultured in vitro. This may because lack an unidentified essential cytokine present vivo. Thus, we investigate interleukin-2...
Epstein‐Barr virus associated lymphoproliferative disease after autologous bone marrow transplantation (ABMT) has rarely been reported. We report a case of B‐cell lymphoma following ABMT for T‐acute lymphoblastic leukaemia; was purged in vitro with monoclonal antibodies to remove T cells. Immunoglobulin and T‐cell receptor gene rearrangement studies were used demonstrate clonality show that this patient developed second neoplasm ABMT. EBV proteins genome (type A) present post‐transplantation...
Summary. Transfusion‐associated graft‐versus‐host disease (TA‐GVHD), has rarely been reported associated with B‐chronic lymphocytic leukaemia (B‐CLL). We report a patient diagnosed B‐CLL, previously treated fludarabine, who developed TA‐GVHD after being transfused during surgery for splenectomy. Diagnosis was confirmed by polymerase chain reaction (PCR) detection of donor DNA in the patient, amplification Y‐chromosome sequence and analysis minisatellite polymorphisms. B‐CLL patients...
Evidence that allogeneic bone marrow transplantation (BMT) can cure or alter the course of intractable autoimmune diseases comes from both extensive experimental work in animal models and anecdotal case reports humans. We describe a female patient diagnosed as having severe aplastic anaemia (SAA), hyperthyroidism ophthalmopathy Graves‐Basedow disease who received BMT her histocompatible sister. Fifty‐three months after BMT, complete remission ocular signs persists. The SAA is cured she free...
Abstract Background Therapeutic phlebotomy (TP), a widely used medical procedure, can be performed on diverse patients with iron overload or polyglobulia. However, its adverse events are not well known as most of the information is derived from healthy blood donors (0.1%–5.3%). In contrast, TP applicable to broader, more complex population comorbidities and old age. To ascertain incidence in phlebotomies, we conducted prospective study who attended our Unit. Study Design Methods We...